Friends
The whole issue of late onset resistance to ibrutinib and other TKIs is a growing area of concern and research.
I will posting more on it in my blog ( bkoffman.blogspot.com ), but Dr. Furman gives us a nice starting perspective.
Stay strong
Brian
Admin: Links now working (HU will not cope with any characters adjacent to the end of the link and it is best to have spaces before and after links.)
Excellent video. Thank you. Made me feel very positive. I am about to start on Ibrutinib.
Exciting times in CLL: an ASCO 2013 interview with Dr Susan O’BrienThree Year Anniversary on Ibrutinib for my CLL
Expert Perspective on Key Trial Updates in Treatment of CLL: What You Need to Know From ASCO/EHA/ICML 2021ASCO 2016: Dr. Susan O’Brien where she discusses frontline data on Acalabrutinib in CLLMe and my CAR-T- Part 1 on why I have moved to Seattle for 2 months
